Reuters logo
BRIEF-KemPharm files IND application for KP484 for the treatment of ADHD
September 20, 2017 / 11:40 AM / 3 months ago

BRIEF-KemPharm files IND application for KP484 for the treatment of ADHD

Sept 20 (Reuters) - KemPharm Inc

* KemPharm files IND for KP484 for the treatment of ADHD, an investigational prodrug of methylphenidate

* KemPharm - ‍Kempharm’s IND proposal is to develop KP484 along similar clinical trial pathway as KP415,with efficacy studies of KP484 initiating in 2018​

* KemPharm Inc - ‍anticipates that data for KP484 will be leveraged from KP415 research, which could allow a potential NDA submission with FDA in 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below